U.S. markets open in 28 minutes

Kiniksa Pharmaceuticals, Ltd. (KNSA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.34+0.04 (+0.39%)
At close: 04:00PM EDT
10.34 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close10.30
Bid7.36 x 1200
Ask13.30 x 800
Day's Range10.07 - 10.58
52 Week Range7.36 - 16.68
Avg. Volume276,298
Market Cap716.311M
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for KNSA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kiniksa Pharmaceuticals, Ltd.
    Analyst Report: AbbVie Inc.AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
    Fair Value
    Economic Moat
    15 days agoMorningstar
View more
  • GlobeNewswire

    Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022

    HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m. Eastern Time to report its first quarter 2022 financial results and corporate activities. A live webcast will be accessible through the Investors & Media section of the company’s website at A replay of the webcast will also be available on Kiniksa’s website within approximately

  • GlobeNewswire

    Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

    – ARCALYST® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 –– ARCALYST collaboration achieved profitability in Q4 2021 –– ARCALYST full-year 2022 net revenue expected to be $115 - $130 million –– Strategic collaboration with Huadong Medicine to develop and commercialize ARCALYST and mavrilimumab in the Asia Pacific Region (excluding Japan) –– Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Kiniksa P

  • GlobeNewswire

    Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration

    – Collaboration includes rights to develop and commercialize ARCALYST® and mavrilimumab in the Asia Pacific Region (excluding Japan) – – Kiniksa to receive $22 million upfront; eligible to receive development and commercial milestone payments and tiered royalties – HAMILTON, Bermuda, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of disea